Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the health care field worldwide. Segments The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics. Consumer Segment The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care, and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The Baby Care franchise includes the JOHNSON’S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON’S Adult; NEUTROGENA; RoC; LUBRIDERM; DABAOtm; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. The Wound Care franchise includes BAND-AID brand adhesive bandages and Neosporin First Aid products. Major brands in the Women’s Health franchise are the CAREFREE Pantiliners; o.b. tampons; and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson • Merck Consumer Pharmaceuticals Co. These products are marketed to the general public and sold both to retail outlets and distributors worldwide. Pharmaceutical Segment The Pharmaceutical segment includes products in the following areas: anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. These products are distributed directly to retailers, wholesalers, and health care professionals for prescription use. Key products in the Pharmaceutical segment include REMICADE (infliximab), a treatment for various immune mediated inflammatory diseases; STELARA (ustekinumab), a treatment for moderate to severe plaque psoriasis; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE (bortezomib), a treatment for multiple myeloma; PREZISTA (darunavir) and INTELENCE (etravirine), treatments for HIV/AIDS; NUCYNTA (tapentadol), a treatment for moderate to severe acute pain; INVEGA SUSTENNA (paliperidone palmitate), for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA (risperidone), a treatment for the management of Bipolar I Disorder and schizophrenia; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), to stimulate red blood cell production; LEVAQUIN (levofloxacin) for the treatment of bacterial infections; CONCERTA (methylphenidate HCl), a treatment for attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a delivery system. Medical Devices and Diagnostics Segment The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories, and clinics. These products include Biosense Webster’s electrophysiology products; Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; Ethicon’s surgical care, aesthetics, and women’s health products; Ethicon Endo-Surgery’s surgical products and sterilization products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products; and Vistakon’s disposable contact lenses. Distribution to these health care professional markets is done both directly and through surgical supply and other dealers. Significant Events In March 2011, Juvenile Diabetes Research Foundation International Inc. had extended its jointly-funded research program with the Johnson & Johnson Corporate Office of Science & Technology, which focused on increasing the development of possible therapeutics that would promote pancreatic beta cell survival and function in individuals with insulin-dependent diabetes. History Johnson & Johnson was founded in 1885.